AstraZeneca's Baxdrostat met the primary and all secondary endpoints in BaxHTN Phase III trial
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
Apotex will also pay US$ 2.5 million upon receipt of final USFDA approval of the ANDA that is the subject of the Collaboration Agreement for Paclitaxel Protein-Bound Particles for Injectable Suspension
Havix is a US based company engaged in the business of developing, manufacturing and supplying of various finished formulations
Emcure Pharmaceuticals successfully completes USFDA PAI of Oncology facility
The company’s largest center for medical device applications, serving the entire Asian market
To streamline complex medical writing workflows with GenAI
IGI partners with AbbVie and grants exclusive rights to globally develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China
Subscribe To Our Newsletter & Stay Updated